AbCellera to Present at the UBS Global Biopharma Conference
AbCellera announced that it will participate in the upcoming UBS Global Biopharma Conference scheduled for November 17, 2026.
Stocks · News reference
AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause
AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Jefferies & Co. Initiates Coverage on AbCellera Biologics with Buy Rating
Jefferies & Co. has initiated coverage on AbCellera Biologics Inc. with a "Buy" rating and a price target of $21.
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera
The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18
AbCellera Presents Phase 1/2 Data On ABCL635 At TMS 2026 Annual Meeting
JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17